pfizer lot numbers lookup

You will be subject to the destination website's privacy policy when you follow the link. Lot Numbers Aggregate Vaccine Counts Search/Add Search Results Detail Correct Decrementing . This applies to COVID-19 vaccines that have received full FDA approval and emergency use authorization. One dose (0.2 mL) contains 10 micrograms of COVID-19 mRNA vaccine. Do not use the vaccine in this shipment until you have received the quality report from Controlant advising on further use. Pfizer Lot Number: FL2757 will be expiring 09/30/2022 (govdelivery.com) Pfizer Lot Number: FL2757 will be expiring 09/30/2022 (PDF) COVID-19 Bivalent Vaccine Authorization (govdelivery.com) IMPORTANT COVID-19 Bivalent Booster Update (govdelivery.com) 2022-2023 Influenza Vaccine Availability and Ordering (govdelivery.com) Review FDAs Draft Guidance for Industry: Electronic Submission of Lot Distribution Reports. The COVID-19 Vaccine Lot Number and Expiration Date Report is available via registration only. Ensure the ID on the card matches a driver's license, then check for appropriate dose intervals. Contact your health care provider if you experience: Health care providers must report possible reactions following vaccination to their local public health authority. FDA is not requiring or recommending that the identified lot numbers in the following table be relabeled with their new use dates. For EUA COVID-19 vaccines that do not have a final expiration date, CDC has set up an expiration date of 12/31/2069 to serve as a placeholder date. Android, The best in medicine, delivered to your mailbox. Here's what you need to know. Saving Lives, Protecting People, COVID-19 Vaccine Breakthrough Case Investigation and Reporting, Clinical Decision Support for Immunization (CDSi), COVID-19 Vaccine Lot Number and Expiration Date Tool, National Center for Immunization and Respiratory Diseases, Use of COVID-19 Vaccines in the U.S.: Appendices, FAQs for the Interim Clinical Considerations, Myocarditis and Pericarditis Considerations, Jurisdictions: Vaccinating Older Adults and People with Disabilities, Vaccination Sites: Vaccinating Older Adults and People with Disabilities, Vaccinating Patients upon Discharge from Hospitals, Emergency Departments & Urgent Care Facilities, Vaccines for Children Program vs. CDC COVID-19 Vaccination Program, FAQs for Private & Public Healthcare Providers, Talking with Patients about COVID-19 Vaccination, Talking to Patients with Intellectual and Developmental Disabilities, How to Tailor COVID-19 Information to Your Audience, How to Address COVID-19 Vaccine Misinformation, Ways to Help Increase COVID-19 Vaccinations, COVID-19 Vaccination Program Operational Guidance, What to Consider When Planning to Operate a COVID-19 Vaccine Clinic, Using the COVID-Vac Tool to Assess COVID-19 Vaccine Clinic Staffing & Operations Needs, Connecting with Federal Pharmacy Partners, Resources to Promote the COVID-19 Vaccine for Children & Teens, COVID-19 Vaccine Access in Long-term Care Settings, Information for Long-term Care Administrators & Managers, Vaccinating Dialysis Patients and Healthcare Personnel, What Public Health Jurisdictions and Dialysis Partners Need to Know, Supporting Jurisdictions in Enrolling Healthcare Providers, Vaccine Administration Management System (VAMS), Resources for Jurisdictions, Clinics, and Organizations, 12 COVID-19 Vaccination Strategies for Your Community, How to Engage the Arts to Build COVID-19 Vaccine Confidence, Strategies for Reaching People with Limited Access to COVID-19 Vaccines, U.S. Department of Health & Human Services. endstream endobj 126 0 obj <. <> All vaccinators should return Controlant DDLs using the return shipping label. Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. This resource is designed to help you determine the appropriate CPT code combination for the type and dose of vaccine that you are using. For COVID-19 questions call800-232-4636 (TTY 888-232-6348) Use Pfizer-BioNTech's expiration date tool at lotexpiry.cvdvaccine.com to determine the vaccine's expiration date. Long-term storage: Ultra Cold -90C to -60C (-130F to -76F)* Do NOT store at -25C to -15C (-13F to 5F). You may also visit the CDC's Vaccine Lot Number and Expiration Date webpage and complete the registration form to request access to COVID-19 vaccine expiration dates. 2022 The State of North Carolina. To receive email updates about this page, enter your email address: We take your privacy seriously. CDC Guidance for Planning Vaccination Clinics Held at Satellite, Temporary, or Off-Site Locations, COVID-19 Vaccination Site Accessibility Checklist (English), COVID-19 Vaccination Site Accessibility Checklist (Spanish), All CDC Guidance on Vaccine Administration, Summary List of User Guides and Previously Recorded Training Sessions, Latest Vaccine Guidance and Information for Providers, How to View Vaccination Information - Provider. These decisions are based on public health recommendations and the latest evidence. CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. How to search and advertise available COVID-19 vaccine for transfer (PDF) WAIIS online transfers (PDF) . Those dates must also be entered into WIR. CDCs COVID-19 Vaccine Expiration Date Tracking Tool can help providers keep track of the expiration date by lot number. Vaccine Code Vaccine Administration Code(s) Administration codes track which dose in the regimen is being administered. This technology is designed primarily to help immunization providers record information about the VIS as is required by the National Childhood Vaccine Injury Act (NCVIA). Selection required to narrow down to correct Administrative Code. An official website of the United States government, Recalls, Market Withdrawals and Safety Alerts, Seasonal Information for Influenza Virus Vaccine, Guidance, Compliance & Regulatory Information (Biologics), http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Stay up to date with what you want to know. The improved data file format provides a standardized and consistent presentation of lot distribution information that can be automatically transferred and validated against FDAs Regulatory Management system, which tracks licensed FDA products and manufacturers. COVID-19 Pfizer BioNTech Vaccine EUA Recipient-Caregiver Fact Sheet; 4/6/2021 253088698300033211201201; 0886983000332 Historic; 5/10/2021 COVID-19 Pfizer BioNTech EUA Recipient-Caregiver Fact Sheet-12 years and older; 12/8/2022 253088698300033211210501; 0886983000332 Historic; 4/18/2023 COVID-19 Novavax EUA Recipient-Caregiver Fact Sheet Cards also provide a space for the name of the vaccine manufacturer (Pfizer-BioNTech, Moderna, Johnson & Johnson), lot number, date of the shot, name of the healthcare provider or clinic that provided the vaccine and when it's time to come in for your second shot, if applicable. Organization Type Other (Describe) The new files include COVID-19 vaccine National Drug Codes (NDCs), lot numbers, and lot expiration dates. %PDF-1.6 % endstream endobj startxref Through v-safe, vaccine recipients canquickly tellCDCif they haveany side effectsafter getting the COVID-19 vaccine. Before sharing sensitive information, make sure you're on a federal government site. COVID-19 Vaccine Lot Number and Expiration Date Tool Seasonal Influenza Codes and Crosswalk This new format includes all seasonal influenza vaccines for the 2022/2023 season in a single Excel crosswalk table that provides the CVX, MVX, NDC Unit of Sale, NDC Unit of Use, and CPT (*) codes for each vaccine. The thermal container maintains a temperature range of -90C to -60C (-130F to -76F). The mRNA sequence from the Pfizer-BioNTech Comirnaty COVID-19 vaccine is also included in the Pfizer-BioNTech Comirnaty Original and Omicron BA.4/BA.5, bivalent COVID-19 vaccine. See more information about vaccine wastage reporting on the COVID-19: General Guidance for Vaccinators page. The bivalent booster also has an additional mRNA sequence that targets the Omicron BA.4/BA.5 variants. An overview of the IT systems and how they integrate to track distribution and administration, A free web-based tool to manage vaccine administration and registration, IIS consolidate immunization information into one reliable source, CDCs vaccine order management system and platform for all COVID-19 vaccine ordering, A cloud-based message routing service intended to enable data exchange, Information for jurisdictions and healthcare providers, Instructions on submitting COVID-19 vaccine administration data to CDC. For assistance with CBER LDD submissions, contact CBERSPL@FDA.HHS.GOV. The dosing schedule approved by Health Canada is to give 2 doses (30 micrograms each for ages 12 and older or 10 micrograms each for ages 5 to 11) 21 days apart, based on evidence from clinical trials. Once you have located the .bin file on your computer, please manually upload this file to. Home Data Catalog Developers Video Guides 176 0 obj <>stream Maroon, orange, and gray cap vials can remain in use for up to 18months beyond the date of manufacture, if stored consistently in an ultra-low temperature freezer. The vials can be stored in the refrigerator for 10 weeks. No ancillary supplies, including COVID-19 vaccine record cards, will be provided with this SDV product. If the test file is compliant with technical requirements, then the LDD system will return an email test acknowledgment receipt with notification for data acceptance. Saving Lives, Protecting People, (Click on a column heading to sort table accordingly), Public Health Information Network (PHIN) Vocabulary Access and Distribution System (VADS), National Center for Immunization and Respiratory Diseases, Core Data Elements For IIS Functional Standards v4.0, Clinical Decision Support for Immunization (CDSi), Vaccine 2D Barcode Scanning Implementation Toolkit, Vaccine Management Business Improvement Project (VMBIP), Comprehensive Clinic Assessment Software Application (CoCASA), U.S. Department of Health & Human Services, Centers for Disease Control and Prevention. As noted previously, the only order quantity available for Wisconsin vaccinators at this time will be50 doses. Vaccine safety has been and will continue to be one of CDCs top priorities. 2) The lot number and expiration date The lot number is a string of numbers and letters that tracks this specific batch of vaccine . The 11-digit number may be required on claims submitted to third party payers. However, review of the specific elements of the card can help you assess for evidence of fraud. For further information/assistance contact SPL@fda.hhs.gov. Mix and match use of the bivalent Pfizer and Moderna COVID-19 vaccines is not currently authorized for children ages 6 months through 4 years. The SDVs may also encourage new sites to enroll as a COVID-19 vaccinator. They help us to know which pages are the most and least popular and see how visitors move around the site. A Quality Report should be provided via email within one to three hours. State Government websites value user privacy. NC Department of Health and Human Services The VIS Lookup Table allows users to link the VIS Fully-Encoded Text String to the corresponding Global Document Type Identifier (GDTI). Step 2 90.7% effective for those 5 to 11 years old. It is important to carefully read the labels to differentiate between the vaccines to ensure children 6 months through 4 years of age receive the appropriate vaccine for each primary series dose. endobj On June 10, 2014, FDA issued a rule which, among other things, amended 21 CFR 600.81 to require applicants to submit Lot distribution reports to FDA in an electronic format that the Agency can process, review and archive. This is the body's immune response, as it's working hard to build protection against the disease. Email / Username. ALC-0315 = ((4-hydroxybutyl) azanediyl)bis (hexane-6,1-diyl)bis(2-hexyldecanoate), ALC-0159 = 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, 1,2-distearoyl-sn-glycero-3-phosphocholine, hives (bumps on the skin that are often very itchy), swelling of the lips, face, tongue or airway, a side effect following vaccination with a COVID-19 vaccine, any persistent, new or worsening symptoms, monitor the use of all COVID-19 vaccines closely, examine and assess any new safety concerns. 5% of the batches appear to have produced 90% of the adverse reactions Some Pfizer batches are associated with 30 x the number of deaths and disabilities compared to other batches Again, this is called "advocate approach". They help us to know which pages are the most and least popular and see how visitors move around the site. Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website. Pfizer and Moderna are two-dose vaccines, while J&J is one dose. 00069-2025-01 . The dosing for 6 months to less than 5 years is a 3-dose primary series of 3 micrograms each of the vaccine. Please follow these steps to begin submitting LDD Reports electronically: Step 1 0 This product information is intended only for residents of the United States. The benefits must also outweigh any risks. While the elements present (other than the CDC seal) are the same as the standard CDC card, the format is different for each nonstandard card. On November 24, Controlant DDLs will no longer be available for continued temporary storage temperature monitoring following the initial delivery of vaccine shipments. x\[o8~G{0UPHtvyPl6XYI6CIm=t:[W~N.e1#nx]b?6l8=I)K'di1mSM<=xLTkx4cFrhzl/OO'%`i oHe@9'_z'Gh? There are two fields contained within the 2D barcode on the VIS. The VIS barcode does not contain any data that is not currently on the VIS, and there is no requirement that immunizers supply VIS data to IIS. The report is available only . As a practicing physician and president of ImmunaBand a company I founded in December 2020 that sells a silicon bracelet with a QR code directing a person to a password-protected copy of their vaccine I've been grappling with this question of authenticating vaccine cards since the rollout of the vaccine. Vials with a purple cap and purple label border contain 6 doses of 0.3 mL after dilution. visit the COVID-19 vaccine development section. Lot Numbers Aggregate Vaccine Counts Search/Add Search Results Detail Correct Decrementing Orders[Transfers Information and resources to help public health departments and laboratories investigate and report COVID-19 vaccine breakthrough cases. CDC INFORMATION. The public health authority then reports them to the Public Health Agency of Canada. Submit a test file using FDA Test environment (provide link to the documentation you have for conducting pilot test). You can review and change the way we collect information below. All information these cookies collect is aggregated and therefore anonymous. The Pfizer-BioNTech COVID-19 vaccine was authorized for use in Canada under the Interim Order respecting the importation, sale and advertising of drugs for use in relation to COVID-19. Copyright 1995 - 2023 American Medical Association. Vaccinators can place orders for Pfizer SDVs by completing the COVID-19 Vaccine Ordering Survey. For enquiries,contact us. Key webpages with clinical resources include: CDC's Pfizer-BioNTech COVID-19 vaccine webpage, FDA's Pfizer-BioNTech COVID-19 vaccine webpage. <>/Font<>/XObject<>/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 612 792] /Contents 4 0 R/Group<>/Tabs/S/StructParents 0>> . Secure .gov websites use HTTPS Data Systems Tracking COVID-19 Vaccine Distribution and Administration, Breakthrough Case Investigations and Reporting, Centers for Disease Control and Prevention. Pfizer-BioNTech COVID-19 Vaccine, Bivalent has not been approved or licensed by FDA, but has been authorized for emergency use by FDA, under an EUA to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals aged 6 months of age and older. The UoS is the Unit of Shipment and is the lot number for the vaccine packaging. As fake vaccine cards become a nationwide problem, it's crucial to know how to verify one. *Cartons of Pfizer-BioNTech COVID-19 Vaccine vials may also arrive at refrigerator temperature 2C to 8C. The National Drug Code (NDC) uniquely identifies human drugs in the United States; it can be found on the vial containing the vaccine. Lot Number . CDC suggests the addition of a field for VIS document type. The emergency use . New weekly allocations of doses are posted every Tuesday. endobj On April 18, 2023, the Food and Drug Administration amended the emergency use authorization (EUA) of Pfizer-BioNTech COVID-19 Vaccine, Bivalent to simplify the vaccination schedule for most . Presentation . This procedure is intended to assist manufacturers of vaccines and other biological products to electronically submit post marketing lot distribution data to FDA under 21 CFR 600.81. The standard CDC card includes an official CDC seal, the person's name, the date of their vaccination, lot numbers, and the site where they received the vaccine. This placeholder date, which is far in the future, is intended to serve as a . Product . The vaccine has been known as the Pfizer-BioNTech COVID-19 vaccine and can be marketed as COMIRNATY (koe-mir-na-tee), for the prevention of COVID-19 disease in individuals 12 years of age and older. The cap colors and vial label borders for both the monovalent and bivalent Pfizer products are gray. Vaccinators are encouraged to use SDVs at sites where they can increase access and availability of the bivalent booster vaccine. You must click the link within the email (unique to the particular device of your shipment) and click through the proper steps to deactivate monitoring. The Pfizer-BioNTech vaccine label remains for individuals aged 6 months to 11years since the vaccine is authorized but not yet approved for these age groups. The CDC itself doesn't propose any specific criteria to assess the authenticity of vaccination cards. With cities like New York and LA as well as many major companies moving toward some kind of vaccine requirement, the question arises as to how employers, restaurant owners, and others can evaluate the validity of vaccine cards, especially as fakes become a nationwide problem. Do not use the Pfizer products beyond 18 months from manufacture date. NDC . The following resources are also available on the above webpages: Contact McKesson MedSurg to reportEmail: snssupport@mckesson.com, Health care personnel or health departments in the U.S. can request a consultation fromThe Clinical Immunization Safety Assessment COVIDvax project websitePhone: 800-CDC-INFO (800-232-4636), COVID-19: Vaccinator Guidance for Pfizer Vaccine, Protecting and promoting the health and safety of the people of Wisconsin, American Rescue Plan Act Funding for Wisconsin, Governor Evers' Proposed 2023-2025 Budget, Statutory Boards, Committees and Councils, PRAMS (Pregnancy Risk Assessment Monitoring System), WISH (Wisconsin Interactive Statistics on Health) Query System, Find a Health Care Facility or Care Provider, Health Insurance Portability and Accountability Act (HIPAA), Long-Term Care Insurance Partnership (LTCIP), Psychosis, First Episode and Coordinated Specialty Care, Services for Children with Delays or Disabilities, Supplemental Security Income-Related Medicaid, Aging and Disability Resource Centers (ADRCs), Services for People with Developmental/Intellectual Disabilities, Services for People with Physical Disabilities, Nutrition, Physical Activity and Obesity Program, Real Talks: How WI changes the conversation on substance use, Small Talks: How WI prevents underage drinking, Health Emergency Preparedness and Response, Home and Community-Based Services Waivers, Medicaid Promoting Interoperability Program, Preadmission Screening and Resident Review, Alcohol and Other Drug Abuse (AODA) Treatment Programs, Environmental Certification, Licenses, and Permits, Health and Medical Care Licensing and Certification, Residential and Community-Based Care Licensing and Certification, stored in either a refrigerator or ultra-cold freezer, ingredient of the Pfizer-BioNTech COVID-19 vaccine, Emergency Use Authorization Fact Sheet for Healthcare Providers Administering Vaccine, Emergency Use Authorization Fact Sheet for Recipients and Caregivers, Pfizer Vaccine Formulation/Presentation Guide, Pfizer-BioNTech COVID-19 Vaccine Expiry Tool, CDC's Vaccine Lot Number and Expiration Date webpage, Administration Overview for Pfizer-BioNTech COVID-19 Vaccine, Pfizer emergency use authorization fact sheet for people ages 12 years and older, COVID-19: General Guidance for Vaccinators page, https://www.pfizermedicalinformation.com/en-us/medical-updates, Food and Drug Administration (FDA) approved, CDC's webpage Pfizer-BioNTech COVID-19 Vaccine Overview and Safety, Comirnaty and Pfizer-BioNTech COVID-19 vaccine webpage, Advisory Committee on Immunization Practices, Comirnaty and Pfizer-BioNTech COVID-19 Vaccine, August 23, 2021 Approval Letter Comirnaty, receiving your single-use Controlant shipment, Controlant Onsite Temperature Monitoring Playbook for Sites, Pfizer's Vaccine Formulation/Presentation Guide, CDC's Pfizer-BioNTech COVID-19 Vaccine Products At-A-Glance, FDA's Pfizer-BioNTech COVID-19 Vaccine Presentations Wall Chart, Pediatric COVID-19 Vaccine Dosing Quick Reference Guide, Children who Transition from a Younger to Older Age Group, Transporting vaccine for vaccination clinics held at satellite, temporary or off-site locations, recipients ages 6 months to 4 years and their caregivers, Beyond use-date (BUD) guidance and labels, recipients ages 5 to 11 years and their caregivers, recipients ages 12 years and older and their caregivers, Clinical Immunization Safety Assessment COVIDvax, Temperature excursions within the clinic or site, A complex COVID-19 vaccine safety question about an individual patient residing in the U.S. not readily addressed by CDC guidance. Access your favorite topics in a personalized feed while you're on the go. Vial labels and cartons may state that after dilution a vial contains five doses of 0.3 mL. Sites that don't are often hospitals or other larger systems. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests. Find a vaccine location near you. Call 800-232-4636. To find the expiration date, enter the lot number found on the vial or the carton into the Pfizer-BioNTech COVID-19 Vaccine Expiry Tool. Use a local account to log in. These cookies may also be used for advertising purposes by these third parties. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use0004A, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 viral particles/0.5mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 viral particles/0.5mL dosage; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 viral particles/0.5mL dosage; second dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 viral particles/0.5mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 viral particles/0.5 mL dosage; booster dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 viral particles/0.5mL dosage, single dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; booster, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; second dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; booster dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, booster dose, Sanofi Pasteur COVID-19 Vaccine, (Adjuvanted For Booster Immunization), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; second dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRN-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, third dose.

Raiders Funny Nicknames, Kensington Tours Vs Abercrombie And Kent, High School Boxing Club, Small Cabin Homes For Sale In Louisiana, Articles P